{
    "id": 5088,
    "name": "mixed epithelial stromal tumour",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5088",
    "evidence": [
        {
            "id": 9915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, epithelial stromal tumor cells of the seminal vescicle from a prostate adenocarcinoma mouse model expressing PDGFRB demonstrated sensitivity to Gleevec (imatinib) in culture, resulting in inhibition of cell proliferation (PMID: 27980106).",
            "molecularProfile": {
                "id": 23627,
                "profileName": "PDGFRB positive"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5088,
                "name": "mixed epithelial stromal tumour",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7757,
                    "pubMedId": 27980106,
                    "title": "Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980106"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}